Recurrent hypersomnia
Methodology & AI Transparency ⓘ
Recurrent hypersomnia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as G47.13, Recurrent hypersomnia falls under Sleep Disorders management, where CBT-I behavioral sleep in Recurrent hypersomnia (G47.13: efficiency tracking) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry G47.13: Recurrent hypersomnia is managed within Sleep Disorders.
- 3 Typical cash cost range: Differential triage of Recurrent hypersomnia (G47.13) utilizes CBT-I behavioral sleep in Recurrent hypersomnia (G47.13: efficiency tracking).
- 4 Top reported side effects / signs: Follow-up benchmark in Recurrent hypersomnia: maintaining Insomnia Severity Index in Recurrent hypersomnia (G47.13: (ISI)) within < 7 (G47.13).
Ask our AI Specialists anything about Recurrent hypersomnia
What Is Recurrent hypersomnia?
Designated in federal medical registries as G47.13, Recurrent hypersomnia falls under Sleep Disorders management, where CBT-I behavioral sleep in Recurrent hypersomnia (G47.13: efficiency tracking) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Recurrent hypersomnia (G47.13) features fragmented slow-wave/REM sleep in Recurrent hypersomnia (G47.13: architecture). therapeutic stabilization in sleep disorders is verified against Nocturnal Oxygen Saturation in Recurrent hypersomnia (G47.13: (SpO2)).
Common Symptoms & Clinical Signs
- • Presentation of Recurrent hypersomnia (G47.13): unrefreshing morning waking in Recurrent hypersomnia (G47.13: despite adequate hours)
- • Secondary Recurrent hypersomnia clinical sign: loud habitual snoring, in Recurrent hypersomnia (G47.13: witnessed breathing pauses,)
- • Symptom flares in Recurrent hypersomnia correlating with Insomnia Severity Index in Recurrent hypersomnia (G47.13: (ISI)) deviation outside < 7 (G47.13)
- • Functional sleep disorders impact requiring CBT-I behavioral sleep in Recurrent hypersomnia (G47.13: efficiency tracking) evaluation (G47.13)
Recurrent hypersomnia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G47.13 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Insomnia Severity Index in Recurrent hypersomnia (G47.13: (ISI)) | < 7 (G47.13) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Nocturnal Oxygen Saturation in Recurrent hypersomnia (G47.13: (SpO2)) | >= 94% nadir > 90% (G47.13) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin (Restless in Recurrent hypersomnia (G47.13: Legs)) | > 75 ng/mL (G47.13) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Recurrent hypersomnia
Treatment selection for Recurrent hypersomnia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Recurrent hypersomnia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Telmisartan to prevent recurrent stroke and heart and blood vessel: What a 20,332-Participant Study Found Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major heart and blood vessel events, or diabetes. The New England journal of medicine • 2008-09-18 • Randomized Controlled Trial | N = 20,332 | 96/100 | PMID 18753639 ↗ |
| New Insights on Re-examining the factor structure of the trouble sleeping Severity Index (ISI): What a 1,956-Participant Study Found A 6-item two-factor scale had better psychometric properties than the 7-item scale in this patient sample. Journal of patient-reported outcomes • 2024-06-29 • Phase III Randomized Trial | N = 1,956 | 96/100 | PMID 38951287 ↗ |
| New Insights on Elevated Lipoprotein(a) Predicts Recurrent heart attack in Diabetic Patients: What a 7,887-Participant Study Found Elevated Lp(a) was associated with increased risk of recurrent MI in patients with diabetes after ACS or PCI. Clinical cardiology • 2026-11-15 • Meta-Analysis | N = 7,887 | 94/100 | PMID 42965402 ↗ |
| New Insights on A phase 3, randomized, gold-standard blind, compared against a dummy pill: What a 298-Participant Study Found Treatment-emergent side effects in both groups were generally mild in severity; there were two moderate events that were judged unrelated to study treatment, and no severe or serious events. The Journal of dermatology • 2023-03-15 • Phase III Randomized Trial | N = 298 | 93/100 | PMID 36353762 ↗ |
| New Insights on Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric: What a 964-Participant Study Found The percentage total weight loss (%TWL) was - 10.97% [95% CI, - 13.41 to - 8.53; p < 0.05] for semaglutide and - 13.63% [95% CI, - 22.59 to - 4.67; p < 0.05] for tirzepatide. Obesity surgery • 2025-12-15 • Meta-Analysis | N = 964 | 91/100 | PMID 41313431 ↗ |
Recurrent hypersomnia Patient Community & “People Like Me” Threads
Filter Recurrent hypersomnia community threads and patient logs by age, biological sex, dosage, and treatment duration.